Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study
R Ramonda, M Lorenzin, A Carriero, MS Chimenti… - RMD open, 2021 - rmdopen.bmj.com
Objectives To evaluate in a multicentric Italian cohort of patients with psoriatic arthritis (PsA)
on secukinumab followed for 24 months:(1) the long-term effectiveness and safety of …
on secukinumab followed for 24 months:(1) the long-term effectiveness and safety of …
Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
PJ Mease, A Kavanaugh, A Reimold, H Tahir… - RMD open, 2018 - rmdopen.bmj.com
Objective To assess the long-term (3 year) efficacy and safety of secukinumab in patients
with active psoriatic arthritis (PsA) in the extension phase of the FUTURE 1 study …
with active psoriatic arthritis (PsA) in the extension phase of the FUTURE 1 study …
Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study
IB McInnes, PJ Mease, AJ Kivitz, P Nash… - The Lancet …, 2020 - thelancet.com
Background Secukinumab is an interleukin-17A inhibitor used in the treatment of patients
with active psoriatic arthritis. In the phase 3 FUTURE 2 trial, secukinumab showed sustained …
with active psoriatic arthritis. In the phase 3 FUTURE 2 trial, secukinumab showed sustained …
Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study
M Megna, L Di Costanzo, G Argenziano… - Expert Opinion on …, 2019 - Taylor & Francis
Background: Long term data on the real-life use of secukinumab are scant. The aim of this
study was to investigate the real-life effectiveness, safety and treatment persistence of …
study was to investigate the real-life effectiveness, safety and treatment persistence of …
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) …
PJ Mease, R Landewé, P Rahman, H Tahir… - RMD open, 2021 - rmdopen.bmj.com
Objective Secukinumab provided sustained efficacy, low radiographic progression and
consistent safety over 52 weeks in patients with psoriatic arthritis (PsA) in the FUTURE 5 …
consistent safety over 52 weeks in patients with psoriatic arthritis (PsA) in the FUTURE 5 …
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
IB McInnes, F Behrens, PJ Mease, A Kavanaugh… - The Lancet, 2020 - thelancet.com
Background Head-to-head trials in psoriatic arthritis are helpful in guiding clinical decision
making. The EXCEED study evaluated the efficacy and safety of secukinumab versus …
making. The EXCEED study evaluated the efficacy and safety of secukinumab versus …
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque …
M Galluzzo, S D'Adamio, D Silvaggio… - Expert Opinion on …, 2020 - Taylor & Francis
Background: There is limited long-term, real-world evidence on the efficacy and safety in
patients with plaque psoriasis treated with secukinumab. We present results at 136 weeks in …
patients with plaque psoriasis treated with secukinumab. We present results at 136 weeks in …
Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5‐year results from the phase 3 FUTURE 1 study
PJ Mease, A Kavanaugh, A Reimold… - ACR open …, 2020 - Wiley Online Library
Objective To report the 5‐year efficacy and safety of secukinumab in the treatment of
patients with psoriatic arthritis (PsA) in the FUTURE 1 study (NCT 01392326). Methods …
patients with psoriatic arthritis (PsA) in the FUTURE 1 study (NCT 01392326). Methods …
Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
TY Ger, YH Huang, RC Hui, TF Tsai… - … advances in chronic …, 2019 - journals.sagepub.com
Background: Little is known about the treatment outcomes of secukinumab in clinical
practice, which differ from those in clinical trials. The effectiveness of biologics may differ in …
practice, which differ from those in clinical trials. The effectiveness of biologics may differ in …
Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain
J Notario, G Deza, E Vilarrasa, F Valentí… - Journal of …, 2019 - Taylor & Francis
Background: The efficacy and safety of secukinumab in patients with plaque psoriasis (PsO)
have been demonstrated in randomized clinical trials (RCTs). However, data regarding its …
have been demonstrated in randomized clinical trials (RCTs). However, data regarding its …